Epinephrine

Generic Name
Epinephrine
Brand Names
Adrenalin, Allerject, Anapen, Articadent, Astracaine, Auvi-Q, Citanest, Citanest Forte, Emerade, Epipen, Lignospan, Marcaine, Marcaine With Epinephrine, Octocaine, Octocaine With Epinephrine, Orabloc, Scandonest, Sensorcaine, Sensorcaine With Epinephrine, Septanest, Septocaine, Symjepi, Ultacan, Ultracaine, Vivacaine, Xylocaine, Xylocaine With Epinephrine, Zorcaine, Eurneffy
Drug Type
Small Molecule
Chemical Formula
C9H13NO3
CAS Number
51-43-4
Unique Ingredient Identifier
YKH834O4BH
Background

Epinephrine, also known as adrenaline, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new produ...

Indication

Epinephrine injection is indicated in the emergency treatment of type I allergic reactions, including anaphylaxis. It is also used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
...

Associated Conditions
Anaphylaxis, Angioneurotic Edema, Bleeding, Bronchospasm, Complete Heart Block, Hypotension, Idiopathic Anaphylaxis, Laryngotracheobronchitis, Mild Intermittent Asthma, Nasal Congestion, Open Angle Glaucoma (OAG), Respiratory Distress, Severe Asthma, Syncope, Type I Hypersensitivity, Urticaria, Uterine Contractions, Ventricular Fibrillation, Resuscitation in cardiac arrest following anesthetic accidents, Severe hypersensitivity reactions, Unresponsive Asystole, Unresponsive Bradycardia
Associated Therapies
-
yahoo.com
·

Frustrated with high drug costs, biohackers are reverse engineering medical treatments

High insulin prices in the U.S. lead diabetics to underground networks, rationing, or crossing borders. Pharmaceutical companies introduced price caps after scrutiny. Biohackers aim to increase access to therapies, providing DIY instructions, but face safety concerns. Critics argue DIY initiatives lack regulatory rigor, potentially harming individuals.
elestoque.org
·

FDA approves neffy, new nasal spray to treat severe allergic reactions

The FDA approved neffy, a nasal spray for treating anaphylaxis, offering advantages like no needle and stable shelf life. While effective, some, like Uma Krishnamoorthy and Jake Tong, remain cautious due to neffy's recent introduction and potential side effects. Krishnamoorthy and Dr. James Wolfe anticipate neffy becoming a viable alternative to EpiPens as it gains more acceptance.

NDA Submission for Anaphylm (Epinephrine) Sublingual Film on Track for Q1 2025, Company Says

Aquestive Therapeutics received positive FDA feedback on its planned NDA submission for Anaphylm (epinephrine) sublingual film, set for early 2025. The FDA agreed with the NDA content and format, endorsed the safety evaluation, and supported the ongoing pediatric trial. No additional adult trials are required, though an advisory committee meeting may precede final decision. Anaphylm could be the first oral epinephrine product for severe allergic reactions, with a projected launch in late 2025 or early 2026.
wpsdlocal6.com
·

Dangerous Food Allergy Reactions: A Drug-Free Life?

A study using omalizumab, originally for asthma, shows promise in treating severe food allergies, allowing children like Anabelle to tolerate nuts. The FDA approved omalizumab in February for severe allergies, usable from age one.
seekingalpha.com
·

Franklin Biotechnology Discovery Fund Q3 2024 Commentary

Global equities rebounded in 3Q24, with health care stocks advancing in July and August, then falling in September. Biotechnology stocks led the sector, driven by factors like interest in innovative weight-loss drugs, easing supply constraints, increased health care utilization, and the sector's defensive nature. Key contributors included Applied Therapeutics, ARS Pharmaceuticals, and Revance Therapeutics. The fund's performance was aided by favorable stock selection, particularly in biotechnology, while detractors included HilleVax and Guardant Health. The outlook remains positive for biotechnology, supported by strong fundamentals, innovation, and M&A activity, despite risks from inflation and the IRA drug pricing measures.
healio.com
·

Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial

IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody therapeutic for peanut allergy, in the ACCELERATE Peanut phase 1 clinical trial. The trial aims to assess safety, tolerability, and proof of mechanism in patients aged 15 years and older. IGNX001 attaches to peanut proteins to neutralize them, differing from other immunotherapies like Palforzia and Xolair. The trial is ongoing in Australia, with recruitment targeting older adolescents and adults, and initial results expected mid-2025.
medwatch.com
·

ALK pays ARS USD 145 billion upfront for nasal spray rights

ALK signs strategic license agreement with ARS Pharma for rights to sell Neffy, a nasal spray containing adrenaline for acute allergic reactions.
globenewswire.com
·

ALK licenses rights to neffy®, the first approved

ALK enters strategic license agreement with ARS Pharma for neffy® adrenaline nasal spray, excluding USA, Australia, New Zealand, Japan, and China. The deal supports ALK's Allergy+ strategy and long-term financial ambitions, with ALK paying USD 145 million upfront and additional milestones and royalties. neffy®, approved in EU and US in 2024, is the first needle-free emergency treatment for anaphylaxis, with potential new indications in acute urticaria. ALK plans to focus on European and Canadian markets initially, with a portfolio approach to meet diverse patient needs.
tcf.org
·

How Pharmacy Benefit Managers Are Harming Patients—and What Policymakers Can Do About It

The FTC sued three major PBMs for inflating insulin prices, highlighting the need for system-wide reform to address high prescription drug prices. Both drug companies and PBMs contribute to high prices, with drug companies setting high list prices and PBMs capturing rebates and using spread pricing. Legislative solutions include requiring PBMs to pass on all savings, reforming the patent system, and expanding Medicare price negotiations.
nature.com
·

Ringer's lactate administered at 15 °C leads to a greater and more prolonged increase in ...

A randomized controlled crossover trial found that cold fluid bolus therapy significantly increased MAP, systemic vascular resistance, and intrinsic noradrenaline levels, without activating adrenaline or the renin–angiotensin–aldosterone system. This prolonged effect on MAP was not observed with fluids at body temperature. The study suggests that fluid temperature, rather than volume alone, contributes to MAP increase in fluid bolus therapy, challenging current physiological principles and potentially offering a cost-effective treatment option for hypotensive patients.
© Copyright 2024. All Rights Reserved by MedPath